Novartis Passes on Idenix Lead HCV Antiviral Drug
Idenix Pharmaceuticals Inc. is looking to partner its early stage compound for hepatic C virus (HCV), now that Swiss drugmaker Novartis Pharma AG has taken a pass on it. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.